Immunovant Inc. (IMVT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data Transcript
Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-of-Concept Study Remission Data Transcript Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Conference Call Participants Samuel Slutsky - LifeSci Capital, LLC, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Samantha Lynn Semenkow - Citigroup Inc. Exchange Research David Risinger - Leerink Partners LLC, Research Division Yaron Werber - TD Cowen, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Douglas Tsao - H.C.
Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack
Roivant Sciences Ltd.'s Vant model gives it risk-isolated development, monetization flexibility, and diversified optionality. ROIV's main value drivers are Immunovant, Priovant, Pulmovant, and Genevant. All of these Vants are progressing well in 2025. However, its main near-term catalyst is Brepocitinib's Phase 3 in dermatomyositis. This could become the first approved therapy for this condition.
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy
Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?
The mean of analysts' price targets for Immunovant (IMVT) points to a 137.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?
Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Immunovant, Inc. reported that positive results were achieved using batoclimab in a phase 3 study to target patients with Myasthenia Gravis; Primary endpoint met. Positive results achieved using batoclimab in phase 2b study targeting patients with Chronic Inflammatory Demyelinating Polyneuropathy; IgG was reduced by ≥ 70%. Data from both phase 3 studies, using batoclimab to treat patients with Active Thyroid Eye Disease, expected 2nd half of 2025.
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.
Immunovant's muscle disorder treatment meets main goal in late-stage trial
Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.
Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Immunovant (IMVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
